PULMONX CORP (LUNG) Stock Fundamental Analysis
NASDAQ:LUNG - US7458481014 - Common Stock
1.67 USD
-0.02 (-1.18%)
1.64 USD
-0.03 (-1.8%)
We assign a fundamental rating of 3 out of 10 to LUNG. LUNG was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LUNG have multiple concerns. LUNG shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
LUNG had negative earnings in the past year.
LUNG had a negative operating cash flow in the past year.
LUNG had negative earnings in each of the past 5 years.
In the past 5 years LUNG always reported negative operating cash flow.
1.2 Ratios
LUNG's Return On Assets of -38.69% is on the low side compared to the rest of the industry. LUNG is outperformed by 63.24% of its industry peers.
The Return On Equity of LUNG (-82.41%) is worse than 60.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.69% | ||
| ROE | -82.41% | ||
| ROIC | N/A |
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUNG's Gross Margin of 73.07% is amongst the best of the industry. LUNG outperforms 83.78% of its industry peers.
LUNG's Gross Margin has been stable in the last couple of years.
LUNG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.07% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
2. Health
2.1 Basic Checks
LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUNG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUNG has been increased compared to 5 years ago.
The debt/assets ratio for LUNG is higher compared to a year ago.
2.2 Solvency
LUNG has an Altman-Z score of -4.07. This is a bad value and indicates that LUNG is not financially healthy and even has some risk of bankruptcy.
LUNG has a worse Altman-Z score (-4.07) than 67.03% of its industry peers.
A Debt/Equity ratio of 0.54 indicates that LUNG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, LUNG is doing worse than 65.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.07 |
ROIC/WACCN/A
WACC8.37%
2.3 Liquidity
A Current Ratio of 5.35 indicates that LUNG has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.35, LUNG is doing good in the industry, outperforming 78.92% of the companies in the same industry.
A Quick Ratio of 4.63 indicates that LUNG has no problem at all paying its short term obligations.
The Quick ratio of LUNG (4.63) is better than 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.35 | ||
| Quick Ratio | 4.63 |
3. Growth
3.1 Past
LUNG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.05%.
The Revenue has grown by 18.23% in the past year. This is quite good.
The Revenue has been growing by 20.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
Revenue 1Y (TTM)18.23%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%14.8%
3.2 Future
LUNG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.67% yearly.
Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 31.30% on average per year.
EPS Next Y-12.35%
EPS Next 2Y-0.13%
EPS Next 3Y7.39%
EPS Next 5Y28.67%
Revenue Next Year10.08%
Revenue Next 2Y12.38%
Revenue Next 3Y15.5%
Revenue Next 5Y31.3%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LUNG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.13%
EPS Next 3Y7.39%
5. Dividend
5.1 Amount
LUNG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.67
-0.02 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners91.98%
Inst Owner Change-1.43%
Ins Owners4.21%
Ins Owner Change13.44%
Market Cap68.05M
Analysts80
Price Target6.89 (312.57%)
Short Float %3.55%
Short Ratio2.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.3%
Min EPS beat(2)6.86%
Max EPS beat(2)11.73%
EPS beat(4)4
Avg EPS beat(4)16.9%
Min EPS beat(4)6.86%
Max EPS beat(4)27.7%
EPS beat(8)8
Avg EPS beat(8)16.79%
EPS beat(12)12
Avg EPS beat(12)13.4%
EPS beat(16)15
Avg EPS beat(16)11.41%
Revenue beat(2)1
Avg Revenue beat(2)-0.02%
Min Revenue beat(2)-0.33%
Max Revenue beat(2)0.28%
Revenue beat(4)2
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)4.53%
Revenue beat(8)6
Avg Revenue beat(8)2.08%
Revenue beat(12)9
Avg Revenue beat(12)2.12%
Revenue beat(16)10
Avg Revenue beat(16)2.02%
PT rev (1m)-39.69%
PT rev (3m)-42.02%
EPS NQ rev (1m)-6.06%
EPS NQ rev (3m)-10.67%
EPS NY rev (1m)-0.7%
EPS NY rev (3m)-0.7%
Revenue NQ rev (1m)-12.43%
Revenue NQ rev (3m)-12.68%
Revenue NY rev (1m)-6.54%
Revenue NY rev (3m)-6.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.75 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.98 | ||
| P/tB | 1.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.43
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS2.22
BVpS1.7
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.69% | ||
| ROE | -82.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.07% | ||
| FCFM | N/A |
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
F-Score2
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 0.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.35 | ||
| Quick Ratio | 4.63 | ||
| Altman-Z | -4.07 |
F-Score2
WACC8.37%
ROIC/WACCN/A
Cap/Depr(3y)78.82%
Cap/Depr(5y)169.58%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
EPS Next Y-12.35%
EPS Next 2Y-0.13%
EPS Next 3Y7.39%
EPS Next 5Y28.67%
Revenue 1Y (TTM)18.23%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%14.8%
Revenue Next Year10.08%
Revenue Next 2Y12.38%
Revenue Next 3Y15.5%
Revenue Next 5Y31.3%
EBIT growth 1Y1.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.63%
EBIT Next 3Y18.96%
EBIT Next 5Y8.94%
FCF growth 1Y23.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.2%
OCF growth 3YN/A
OCF growth 5YN/A